8-K: MAIA Biotechnology Announces Phase 3 Trial for THIO in Lung Cancer

MAIA Biotechnology plans to initiate a Phase 3 trial (THIO-104) to evaluate THIO sequenced with a checkpoint inhibitor in third-line non-small cell lung cancer patients.

Summary

• MAIA Biotechnology is initiating a Phase 3 pivotal trial, THIO-104, to assess the efficacy of THIO in sequence with a checkpoint inhibitor (CPI) for third-line non-small cell lung cancer (NSCLC) patients.
• The trial will compare THIO sequenced with CPI to chemotherapy in a 1:1 randomization of up to 300 patients.
• Patient enrollment is expected to begin in the second half of 2025 across select countries in Asia, Europe, and the U.S.
• The primary endpoint is overall survival, while secondary endpoints include disease control rate, overall response rate, duration of response, progression-free survival, and safety.

Sentiment

Score: 7

Explanation: The announcement of a Phase 3 trial is generally positive, indicating progress in the development of THIO. However, the inherent risks associated with clinical trials and regulatory approvals temper the overall sentiment.

Positives

• Initiation of a Phase 3 trial represents a significant milestone for MAIA Biotechnology and its THIO program.
• The trial design includes a direct comparison to chemotherapy, potentially providing strong evidence of THIO's efficacy.
• The study targets a patient population with limited treatment options (third-line NSCLC resistant to checkpoint inhibitors and chemotherapy).
• Positive results from the THIO-104 trial could lead to FDA commercial approval of THIO.

Risks

• The success of the trial is subject to the usual risks associated with clinical trials, including patient enrollment, data integrity, and regulatory approvals.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated.

Future Outlook

MAIA expects the results from the THIO-104 study to further illuminate THIO's benefits for advanced stage NSCLC patients and mark an important milestone toward FDA commercial approval.

Management Comments

• Vlad Vitoc, M.D., CEO of MAIA, stated that THIO-104 will provide direct comparative data from a randomized study in third-line treatment patients.
• Dr. Vitoc believes the results will further illuminate THIO's unmatched benefits for advanced stage NSCLC patients.
• Dr. Vitoc added that the initiation of THIO-104 will mark an important milestone along MAIA's goal for THIO's FDA commercial approval.

Industry Context

The trial addresses an unmet need in NSCLC patients who have progressed after checkpoint inhibitor and chemotherapy treatment, a growing population as immunotherapy becomes more prevalent. Success could position MAIA as a leader in targeted telomere therapy.

Comparison to Industry Standards

• The trial design, comparing THIO sequenced with CPI to chemotherapy, aligns with standard practices for evaluating new cancer therapies.
• Checkpoint inhibitors such as Keytruda (Merck) and Opdivo (Bristol-Myers Squibb) are established treatments for NSCLC, making the comparison relevant.
• The focus on third-line treatment reflects the need for new options for patients who have exhausted standard therapies.

Stakeholder Impact

• Positive trial results could benefit shareholders through increased stock value.
• Successful development of THIO could provide a new treatment option for NSCLC patients, improving their quality of life.
• Employees may benefit from the company's growth and success.

Next Steps

• Begin enrolling patients in THIO-104 in the second half of 2025 in select countries in Asia, Europe and in the U.S.

Key Dates